RaQualia Pharma (TSE:4579) Other Current Liabilities: 円195 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
59 GF Score
Price 円462.00
GF Value 円310.51
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Other Current Liabilities?

RaQualia Pharma TSE:4579 +0.87% 59 Other Current Liabilities is 円195 Mil as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 59/100 and a GF Value™ of 円310.51 (Significantly Overvalued). The stock has 4 warning signs investors should review.

RaQualia Pharma's other current liabilities for the quarter that ended in Mar. 2026 was 円195 Mil.

RaQualia Pharma's quarterly other current liabilities increased from Sep. 2025 (円108 Mil) to Dec. 2025 (円290 Mil) but then declined from Dec. 2025 (円290 Mil) to Mar. 2026 (円195 Mil).

RaQualia Pharma's annual other current liabilities increased from Dec. 2023 (円80 Mil) to Dec. 2024 (円324 Mil) but then declined from Dec. 2024 (円324 Mil) to Dec. 2025 (円290 Mil).

RaQualia Pharma Other Current Liabilities Related Terms

RaQualia Pharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Other Current Liabilities Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.33 83.04 79.64 324.07 289.56

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.84 185.78 108.24 289.56 195.28
TSE:4579
59GF Score
RaQualia Pharma Inc TSE:4579
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円195 Mil mean?
RaQualia Pharma (TSE:4579) has a Other Current Liabilities of 円195 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on RaQualia Pharma.
Is RaQualia Pharma's Other Current Liabilities too high?
RaQualia Pharma's current Other Current Liabilities is 円195 Mil. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Other Current Liabilities compare to VRTX and REGN?
RaQualia Pharma's Other Current Liabilities of 円195 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on RaQualia Pharma. RaQualia Pharma's current Other Current Liabilities is 円195 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.51, compared to a current price of 円462.00 — trading 48.8% above its estimated fair value. The current Other Current Liabilities is 円195 Mil. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Other Current Liabilities is 円195 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円462.00 is trading 48.8% above its estimated GF Value™ of 円310.51. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Other Current Liabilities: 円195 Mil
  • GF Value™: 円310.51 vs. price of 円462.00 (48.8% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score

Get the complete analysis for TSE:4579

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円462.00
Price
円310.51
GF Value